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Objectives. This study was designed to determine whether atrial 
natriuretic peptide and skeletal aipha-actin messenger RNAs 
(mRNAs) are co-localized in ventricular myocytes of patients with 
dilated cardiomyopathy. 
Background. Atrial natriuretic peptide and skeletal alpha-actin 
are known as augmented genes with cardiac hypertrophy. How- 
ever, the expression and localization of both genes in chronic 
failing heart remain unclear. 
Methods. Left ventricular biopsy specimens were obtained from 
14 patients with dilated cardiomyopathy. Atrial natriuretie pep- 
tide and skeletal alpha-actin mRNAs were detected by in situ 
hybridization with specific sulfur-35 uridine triphosphate-labeled 
RNA probes in the serial sections. 
Results. Atrial natriuretic peptide mRNA was detected in 10 
patients, and intense signals were localized in the myocytes 
located in the subendocardium and around the interstitial fibrous 
area. By contrast, skeletal alpha-actin mRNA was homogeneously 
detected in all myocytes in seven patients. By left ventriculogra- 
phy, patients with skeletal alpha-actin-positive findings had a 
lower ejection fraction (37.1 -+ 6.0%) than those with negative 
findings (46.3 -+ 5.8%, p < 0.05), but atrial natriuretic peptide 
mRNA expression was not related to left ventricular function. 
Conclusions. These results indicate that the expression of atrial 
natriuretic peptide and skeletal alpha-actin mRNAs are not 
always co-localized in the left ventricle of patients with dilated 
cardiomyopathy and suggest hat the mechanisms of the regula- 
tion of these two genes in the chronic failing heart are different. 
(J Am Coll Cardiol 1995;26:85-92) 
Atrial or A-type natriuretic peptide possesses potent natri- 
uretic, diuretic and vasodilatory effects (1-4). Atrial natriuretic 
peptide is synthesized and secreted predominantly b  atrial 
myocytes (5,6); the ventricular contribution to atrial natriuretic 
peptide production is low in the normal adult heart. However, 
atrial natriuretic peptide is expressed in the ventricles during 
early developmental stages (7-10) and is reexpressed in the 
ventricles during cardiac hypertrophy provoked by acute pres- 
sure overload in rats (10,11). Skeletal alpha-actin, one of the 
major contractile protein isoforms of skeletal muscle, is also 
expressed in rat ventricles during fetal development (10) and 
hypertrophy provoked by overload (10,12,13); normal adult 
ventricles contain only small amounts of skeletal alpha-actin 
messenger RNA (mRNA). Thus, the expression of atrial 
natriuretic peptide and skeletal alpha-actin mRNAs in rat 
From The Second Department of Internal Medicine, Tokyo Medical and 
Dental University and *The Second Department of Pathology, Tokyo Women's 
Medical College, Tokyo, Japan. This study was supported in part by a Research 
Grant for Intractable Diseases from the Japanese Ministry of Health and 
Welfare, by Grants-in-Aid 04670560, 6470522 for General Scientific Research 
from the Ministry of Education and by an Open Research Grant from The Japan 
Research Promotion Society for Cardiovascular Disease, Tokyo, Japan. 
Manuscript received August 12, 1994; revised manuscript received February. 
28, 1995, accepted March 2, 1995. 
Address for correspondence: Dr. Michiaki Hiroe, Division of Cardiology,. 
The Second Department of Internal Medicine, Tokyo Medical and Dental 
University, 1-5-45 Yushima, Bunkyo-ku. Tokyo 113, Japan. 
ventricles is thought o be coordinated both during develop- 
ment and in hypertrophy. 
The expression of these two genes in the diseased human 
heart has remained unclear. It has been reported (14-17) that 
atrial natriuretic peptide mRNA and protein are abundant in 
the ventricles of the failing human heart. However, atrial 
natriuretic peptide is not expressed in all ventricular myocytes 
(18-21), and the mechanism of heterogeneous expression is 
not clear. Although several researchers (22-24) have investi- 
gated the presence of skeletal alpha-actin mRNA in the 
ventricles of the diseased human heart, it remains controversial 
whether skeletal alpha-actin mRNA is increased in the ventri- 
cles of the diseased heart. 
We therefore undertook the present study to determine 
whether atrial natriuretic peptide and skeletal alpha-actin 
mRNAs are expressed in the left ventricular myocytes of 
chronic failing heart and whether the distributions of these two 
gene expressions are identical. Furthermore, we addressed the 
question of whether the expression of either of these two genes 
correlates with left ventricular function. To answer these 
questions, we performed in situ hybridization studies in left 
ventricular biopsy specimens from patients with dilated ear- 
diomyopathy, using the specific RNA probes for atrial natri- 
uretic peptide and skeletal alpha-actin, and compared the 
corresponding mRNA expression with variables of left ventric- 
ular function. 
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Table 1. Patient Profiles 
Echocardiography 
Age CFR LVEF LVD(d) IVS 
(yr)/Gender NYHA (%) (%) (turn) %FS (mm) 
DCM group 
50/M I 57 49 57 26 9 
47/M l 53 48 61 17 10 
77,qVl I 52 46 62 15 11 
48/M I 57 38 65 27 14 
46/M I 56 53 52 30 10 
48/M I 46 37 61 18 8 
20/M I 56 31 61 29 10 
38/M 1 55 39 61 21 1l 
46/M II 65 36 68 12 11 
44/F II 48 51 50 26 8 
51/M I1 57 43 59 24 10 
44/M II 59 38 55 28 10 
56/M II 52 29 55 30 7 
36/M ]II 53 46 60 31 10 
Control group 
74/M I 50 65 45 35 8 
57/F I 41 64 44 39 8 
66//vl 1 50 611 37 38 12 
CTR = cardiothoracic ratio; DCM = dilated cardiomyopathy; F = female; FS = fractional shortening; IVS = 
intraventricular septal thickness; LVD(d) : left ventricular end-diastolic dimension; LVEF = left ventricular ejection 
fraction; M - male; NYHA = New York Heart Association functional class. 
Methods  
Patients. Fourteen patients with dilated cardiomyopathy 
(12 men, 2 women; mean [_SD] age 46.5 _+ 12.3 years, range 
20 to 77) were studied (Table 1). All patients with dilated 
cardiomyopathy ad a low left ventricular ejection fraction 
(<55%), diffuse hypokinesia of the left ventricle by left 
ventriculography and no abnormal findings in any coronary 
arteries by angiography. Three patients (two men, one woman; 
mean age 65.7 ___ 8.5 years) thought o have cardiomyopathy 
because of ventricular arrhythmia but had no significant patho- 
logic findings at cardiac biopsy were used as control subjects. 
Several biopsy specimens were obtained from the left ventricle 
with a 7F long sheath and a 7F bioptome (Mansfield, Boston 
Scientific Corporation). Samples were usually taken near the 
posterolateral wall, and histologic examination was performed 
with hematoxylin-eosin staining. Each patient gave written 
informed consent. 
Hemodynamic measurements, Echocardiography and left 
ventriculography were performed in all patients. Two- 
dimensional echocardiograms were recorded with a hand-held 
3.75-MHz transducer at a paper speed of 50 mm/s. End- 
diastolic and end-systolic left ventricular dimensions and intra- 
ventricular septal wall thickness were measured. The percent 
left ventricular f actional shortening was calculated as follows: 
(Left ventricular end-diastolic dimension - Left ventricular 
end-systolic dimension)/Left ventricular end-diastolic dimen- 
sion. Left ventricular ejection fraction was calculated by con- 
trast ventriculography (25) at the time of endomyocardial 
biopsy. 
Preparation of RNA probes. A 680-base pair (bp) fragment 
of human atrial natriuretic peptide complementary DNA 
(cDNA) (26) and a 136-bp fragment of the 3' untranslated 
region of human skeletal alpha-actin cDNA were subcloned 
separately into Bluescript II vector (Stratagene). After linear- 
ization of each plasmid with appropriate restriction enzymes, 
antisense and sense single-strand cRNA probes were synthe- 
sized with sulfur-35-1abeled uridine triphosphate using T7 and 
T3 RNA polymerases. Template DNAs were digested with 
deoxyribonuclease I (Boehringer Mannheim, Mannheim, Ger- 
many), and atrial natriuretic peptide cRNA was then incubated 
with sizing solution (40 mmol/liter sodium bicarbonate, 
60 mmol/liter sodium carbonate, 5 retool/liter dithiothreitol) 
followed by ethanol precipitation. 
In situ hybridization. Left ventricular endomyocardial bi- 
opsy specimens were fixed in 4% paraformaldehyde with 0.5% 
glutaraldehyde and embedded in low melting point paraffin. 
All samples were preserved at -80°C until in situ hybridization 
was performed. After removal of paraffin with xylene, the 
sections were digested with 100 ~g/ml of proteinase K (Boehr- 
inger Mannheim) in 10 mmol/liter Tris-hydrochloride (pH 7.6) 
and 1 mmol/liter ethylenediaminetetraacetic acid (EDTA) for 
10 min at room temperature. The hybridization buffer con- 
tained 0.6 tool/liter sodium chloride, 1 retool/liter EDTA, 
10 mmol/liter Tris-hydrochloride (pH 7.6), 10% dextran sul- 
fate, 0.25% sodium dodecyl sulfate, 200 /xg/ml of transfer 
RNA, 1 × Denhardt's solution, 10 mmol/liter dithiothreitol and 
50% (v/v) deionized formamide. Fifty microliters of the hy- 
bridization buffer containing antisense or sense complemen- 
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tary RNA (cRNA) probes was applied to all sections, followed 
by incubation in a moist chamber with 2x sodium citrate/ 
sodium chloride buffer (SSC) and 50% formamide for 16 h at 
50°C. Then, the sections were washed in 2× SSC and 50% 
formamide for 30 min at 50°C and incubated with 20/xg/ml of 
RNase A (Boehringer Mannheim) for 30 rain at 37°C. After 
washing in 2× SSC for 20 min and 0.2× SSC for 20 min at 50°C 
twice, the sections were dipped into the autoradiographic 
emulsion NTB 3 (Kodak) and kept in light-proof boxes for 1 to 
2 weeks. After photographic development, the sections were 
stained with hematoxylin-eosin. 
Statistical analysis. Results are expressed as mean values _+ 
SD and were analyzed by a two-tailed Student unpaired t test. 
Differences were considered significant at p < 0.05. 
Resu l ts  
Localization of atrial natriuretic peptide mRNA. Figures 
1A and B show the specificity of cRNA probes of atrial 
natriuretic peptide used for in situ hybridization. In situ 
hybridization studies with antisense RNA probes revealed 
strong atrial natriuretic peptide mRNA signals in myocytes of 
right atrial tissue obtained from patients with angina pectoris 
during cardiac surgery (Fig. 1A). In control experiments with 
an atrial natriuretic peptide sense RNA probe, only diffuse 
background labeling was observed over the sections (Fig. 1B). 
Figure 1. Specificity ofcomplementary RNA (cRNA) probes for atrial 
natriuretic peptide and skeletal pha-actin messenger RNAs in the in 
situ hybridization study. A, Atrial natriuretic peptide antisense probe. 
B, Atrial natriuretic peptide sense probe. C, Skeletal alpha-actin 
antisense probe. D, Skeletal lpha-actin sense probe. Tissue was from 
the right atrium of patients with angina pectoris (A and B) or the left 
ventricle of patients with dilated cardiomyopathy (C and D). Intense 
signals are detected in the myocytes bymeans of antisense cRNA for 
atrial natriuretic peptide (A) and skeletal pha-actin (C). Only diffuse 
background labeling is seen using sense cRNA probes for atrial 
natriuretic peptide (B) and skeletal pha-actin (D). Original magnifi- 
cation z25, reduced by 25%. 
Atrial natriuretic peptide mRNA was not detected in 
myocytes from the left ventricle of any of the three control 
patients (data not shown). In 10 of 14 patients with dilated 
cardiomyopathy, atrial natriuretic peptide mRNA was present 
in myocytes of the left ventricles (Fig. 2). In the atrial 
natriuretic peptide mRNA-positive patients, atrial natriuretic 
peptide signals were not detected in all myocytes homoge- 
neously but were localized in specific regions of the tissue. A 
marked accumulation f atrial natriuretic peptide mRNA was 
observed in myocytes located in the subendocardium (Fig. 3A 
and E) and the interstitial fibrous area (Fig. 2), whereas other 
regions in the same sections appeared scarcely labeled. 
Localization of skeletal alpha-aetin mRNA. Figure 1C and 
D show the specificity of cRNA probes of skeletal alpha-actin 
used for in situ hybridization. In situ hybridization with anti- 
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Figure 2. Localized istribution ofatrial natriuretic pcptide messen- 
ger RNA (mRNA) in myocytes in the interstitial fibrous area of the left 
ventricle of patients with dilated cardiomyopathy by in situ hybridiza- 
tion. A and C, Light field. B and D, Dark field. The striking accumu- 
lation of atrial natriuretic peptide mRNA is seen in the myocytes 
located in the interstitial fibrous area. Original magnification ×50, 
reduced by 25%. 
sense RNA probes revealed intense skeletal alpha-actill 
mRNA signals in myocytes of the left ventricle from patients 
with dilated cardiomyopathy (Fig. I C), whereas diffuse back- 
ground labeling was observed over the sections with a sense 
RNA probe (Fig. 1D). 
As with atrial natriuretic peptide mRNA, signals of 
skeletal alpha-actin mRNA were not detected in left ven- 
tricular myocytes of control patients (data not shown). Of 14 
patients with dilated cardiomyopathy, 7 showed the signals 
of skeletal alpha-actin mRNA. In skeletal alpha-actin 
mRNA-positive patients, skeletal alpha-actin mRNA signals 
were distributed homogeneously in almost all myocytes of 
left ventricular tissues. Figure 3 shows the difference in 
atrial natriuretic peptide and skeletal alpha-actin mRNA 
distributions in patients positive for both mRNAs. The 
intense signals of atrial natriuretic peptide mRNA were 
observed in the myocytes located in the subendocardium, 
but the signals were scarcely found in myocytes away from 
the endocardium. By contrast, skeletal alpha-actin mRNA 
was homogeneously detected in all myocytes over sections, 
and the distribution of skeletal alpha-actin mRNA was 
different from that of atrial natriuretic peptide mRNA. The 
intracellular localization of atrial natriuretic peptide and 
skeletal alpha-actin mRNAs also appeared to differ in that 
the grains of skeletal alpha-actin mRNA were diffusely 
scattered throughout he cytoplasm of each myocyte, 
whereas atrial natriuretic peptide mRNA was concentrated 
around nuclei of myocytes. 
Relation of atrial natriuretic peptide and skeletal alpha- 
actin mRNA expression to variables of left ventricular func- 
tion. Patients with dilated cardiomyopathy and skeletal alpha- 
actin mRNA-positive findings had a lower left ventricular 
ejection fraction than those with negative findings (37.1 __ 
6.0% vs. 46.3 _+ 5.8%, respectively, p < 0.05). Left ventricular 
end-diastolic dimension was not different between skeletal 
alpha-actin mRNA-positive and -negative groups (60.1 _+ 4.5 
vs. 58.0 +_ 5.4 ram, respectively, p > 0.1) (Fig. 4A). There were 
no significant differences between atrial natriuretic peptide 
mRNA-positive and -negative groups with regard to left 
ventricular ejection fraction (39.9 _+ 7.3% vs. 46.3 _+ 6.2%, 
respectively, p > 0.1) and left ventricular end-diastolic 
dimension (58.9 _+ 4.9 vs. 59.5 + 5.4 mm, respectively, p > 
0.1) (Fig. 4B). 
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Discuss ion  
The present study showed that atrial natriuretic peptide and 
skeletal alpha-actin mRNA are expressed in left ventricular 
myocytes of patients with dilated cardiomyopathy, although 
neither mRNA was detectable in control hearts. We also 
observed significant differences in the distribution of atrial 
natriuretic peptide and skeletal alpha-actin mRNA in left 
ventricular myocytes of patients with dilated cardiomyopathy, 
indicating that the mechanisms regulating the two genes differ 
in failing human hearts. 
It has been reported that both atrial natriuretic peptide and 
skeletal alpha-actin mRNA are augmented by humoral and 
growth factors, including norepinephrine (27), angiotensin II 
(28), basic fibroblast growth factor (29), transforming growth 
factor-beta (30) and endotbelin 1 (31) in association with 
hypertrophy in cultured rat neonatal cardiomyocytes in vitro. It 
has also been reported that mechanical loading also induces 
hypertrophy of cardiomyocytes and increases of atrial natri- 
uretic peptide and skeletal alpha-actin mRNAs coordinately in 
vitro (32,33) and in vivo (10-13). These findings suggest that 
the atrial natriuretic peptide and skeletal alpha-actin genes 
Figure 3. Differential distribution fatrial natriuretic peptide messen- 
ger RNA (mRNA) and skeletal pha-actin mRNA in the left ventricle 
of patients with dilated cardiomyopathy by in situ hybridization (see 
page 90 for E to H). Myocytes inthe subendocardial layer show intense 
atrial natriuretic peptide mRNA signals (A and E). C and G, Same 
myocytes, respectively, dark field. In contrast, skeletal alpha-actin 
mRNA shows a homogeneous di tribution (Band F). D and H, dark 
field views of respective tissues. Original magnification: A to D x50, E 
to H xl0, all reduced by 25%. 
may be regulated ina related manner in the rapid induction of 
cardiac hypertrophy. Although the mechanism by which such 
coordinated gene regulation might be achieved remains un- 
clear, previous reports have shown that both atrial natriuretic 
peptide (34) and skeletal alpha-actin (35) genes have a binding 
site for the c-fos/c-jun complex, the mRNAs of which are 
expressed before cardiac hypertrophy. 
Localization of atrial natriuretic peptide mRNA. However, 
few studies have examined the regulation of atrial natriuretic 
peptide and skeletal alpha-actin gene expression i the chronic 
stage of cardiac hypertrophy and in heart failure in humans. 
The present study showed that atrial natriuretic peptide 
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Figure 3. Continued. 
mRNA is distributed inhomogeneously in left ventricular 
myocytes of patients with dilated cardiomyopathy. An intense 
accumulation ofatrial natriuretic peptide mRNA was apparent 
in myocytes located in the subendocardium and interstitial 
fibrous area. A nonuniform distribution of atrial natriuretic 
peptide immunoreactivity was previously demonstrated in ven- 
tricular myocytes of dilated cardiomyopathy (18-21). This 
localized expression of atrial natriuretic peptide may result 
from different hresholds of corresponding enes among the 
myocytes of dilated cardiomyopathy. Alternatively, atrial na- 
triuretic peptide xpression i  the ventricle of dilated cardiom- 
yopathy may be affected mainly by regional circumstances, 
such as local mechanical factors or some neurohormonal 
factors produced by cardiac fibroblasts in a paracrine manner. 
Localization of skeletal alpha-aetin mRNA. By contrast, 
skeletal alpha-actin mRNA expression was homogeneously 
detected in left ventricular myocytes of patients with dilated 
cardiomyopathy. Although the mechanism of gene regulation 
for skeletal alpha-actin also remains unclear in dilated car- 
diomyopathy, the finding that the expression of skeletal alpha- 
actin mRNA occurs in almost all myocytes throughout biop- 
sled left ventricular tissue suggests that the trigger for 
induction of the skeletal alpha-actin gene is similar for all 
myocytes without regard to their location. Skeletal alpha-actin 
mRNA was previously detected throughout the entire left 
ventricle after experimental aortic coarctation in rats (13). 
Thus, in contrast o atrial natriuretic peptide mRNA, the 
expression of skeletal alpha-actin mRNA in both rapidly 
induced cardiac hypertrophy and chronic failing myocardium 
may be influenced predominantly b global stress rather than 
by regional conditions. 
Different distribution of atrial natriuretic peptide and 
skeletal alpha-actin mRNA. We also observed that the intra- 
cellular localization of skeletal alpha-actin mRNA was rela- 
tively different from that of atrial natriuretic peptide mRNA. 
The grains for skeletal alpha-actin mRNA were diffusely 
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Figure 4. Skeletal (Sk) alpha-actin messenger RNA 
(mRNA) (A) and atrial natriuretic peptide (ANP) 
mRNA expression (B) in relation to left ventricular 
ejection fraction (LVEF) and left ventricu|ar end- 
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distributed throughout the myocyte cytoplasm, whereas those 
for atrial natriuretic peptide mRNA were concentrated around 
the nuclei of myocytes. A previous report (36) has described 
myosin heavy-chain mRNA in intermyofibrillar space detected 
by electron microscopic in situ hybridization, indicating that 
corresponding mRNA might exist in free ribosomes. That 
study and our results uggest hat mRNAs for the contractile 
protein are located in intermyofibrillar ibosomes of cardiac 
myocytes. 
Relation between cardiac function and skeletal alpha-actin 
or atrial natriuretic peptide mRNA. The present study re- 
vealed that skeletal alpha-actin mRNA-positive patients with 
dilated cardiomyopathy exhibit a lower left ventricular ejection 
fraction than patients with negative findings, suggesting that 
the expression of skeletal alpha-actin mRNA may increase 
concomitantly with reduction of left ventricular function. 
There have been a few reports on skeletal alpha-actin mRNA 
levels in human hearts, and it is controversial whether the 
skeletal alpha-actin mRNA level in diseased hearts is relatively 
higher than that in normal hearts (22-24). Our results uggest 
that chemical or mechanical stress resulting from impaired 
cardiac function may be responsible for the increase in skeletal 
alpha-actin transcript levels. 
Summary. The present study shows that atrial natriuretic 
peptide and skeletal alpha-actin mRNAs show different distri- 
butions in the left ventricle of patients with dilated cardiomy- 
opathy. Furthermore, we showed that skeletal alpha-actin 
mRNA levels, but not atrial natriuretic peptide levels, were 
related to impairment of left ventricular function. These 
results uggest hat the mechanisms of regulation of these two 
muscle-specific genes are different in diseased failing heart. 
We are grateful to Dr. Hisayuki Matsuo for providing cDNA for human atrial 
natriuretic peptide, Dr. Larry Kedes for providing cDNA for human skeletal 
alpha-actin and Dr. Takeshi Kasajima for critical review of this experiment. 
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